Publikationer av Sophia Hober

Refereegranskade

Artiklar

[1]

J. Yan et al., "Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease," Molecular Therapy, vol. 32, no. 2, s. 540-555, 2024.

[2]

U. Marking et al., "Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in sweden," The Lancet - Infectious diseases, vol. 24, no. 2, s. e80-e81, 2024.

[3]

U. Marking et al., "7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection," The Lancet - Infectious diseases, vol. 23, no. 2, s. 150-152, 2023.

[4]

M. Möller et al., "An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries," Protein Engineering Design & Selection, vol. 36, 2023.

[5]

J. Scheffel et al., "Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH," Journal of Chromatography A, vol. 1694, s. 463902, 2023.

[6]

M. Wolf-Watz et al., "Calcium-dependent protein folding in a designed molecular switch," Biophysical Journal, vol. 122, no. 3S1, 2023.

[7]

U. Marking et al., "Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers," Nature Communications, vol. 14, no. 1, 2023.

[8]

O. Bragina et al., "Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [^99mTc]Tc-ADAPT6 and [^99mTc]Tc-(HE)₃-G3, for Imaging of HER2-Positive Breast Cancer," Cancers, vol. 15, no. 12, 2023.

[9]

O. Bladh et al., "Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose," The Lancet Microbe, vol. 4, no. 7, s. 488, 2023.

[10]

A. Abouzayed et al., "The GRPR Antagonist [Tc-99m]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial : Kit Preparation, Characterization and Toxicity," Diagnostics, vol. 13, no. 9, s. 1611, 2023.

[11]

S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, s. 46-52, 2022.

[12]

S. Appelberg et al., "A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells," EMBO Molecular Medicine, vol. 14, no. 10, 2022.

[13]

S. Havervall et al., "Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection," New England Journal of Medicine, vol. 387, no. 14, s. 1333-1336, 2022.

[14]

K. Asplund Högelin et al., "B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients," European Journal of Neurology, vol. 29, no. 11, s. 3317-3328, 2022.

[15]

M. Jönsson et al., "CaRA – A multi-purpose phage display library for selection of calcium-regulated affinity proteins," New Biotechnology, vol. 72, s. 159-167, 2022.

[16]

L. Blixt et al., "Covid-19 in patients with chronic lymphocytic leukemia : clinical outcome and B- and T-cell immunity during 13 months in consecutive patients," Leukemia, vol. 36, no. 2, s. 476-481, 2022.

[17]

J. Scheffel et al., "Design of an integrated continuous downstream process for acid-sensitive monoclonal antibodies based on a calcium-dependent Protein A ligand," Journal of Chromatography A, vol. 1664, s. 462806-462806, 2022.

[18]

V. Tolmachev et al., "Direct In Vivo Comparison of Tc-99m-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy," International Journal of Molecular Sciences, vol. 23, no. 23, 2022.

[19]

U. Marking et al., "Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines," Vaccines, vol. 10, no. 3, s. 359, 2022.

[20]

J. Garousi et al., "Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts : Efficacy and Selection of Companion Imaging Counterpart," Pharmaceutics, vol. 14, no. 8, 2022.

[21]

M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," Metabolic engineering, vol. 72, s. 171-187, 2022.

[22]

K. Blom et al., "Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection," The Lancet - Infectious diseases, vol. 22, no. 7, s. 943-945, 2022.

[23]

S. Havervall et al., "Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time," Clinical & Translational Immunology (CTI), vol. 11, no. 4, 2022.

[24]

H. Schwarz et al., "Integrated continuous biomanufacturing on pilot scale for acid-sensitive monoclonal antibodies," Biotechnology and Bioengineering, 2022.

[25]

I. Lauren et al., "Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology," Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.

[26]

S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, s. 72-80, 2022.

[27]

S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, s. e0262169-e0262169, 2022.

[28]

K. Healy et al., "Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals," MED, vol. 3, no. 2, s. 137-153, 2022.

[29]

E. von Witting, S. Hober och S. Kanje, "Affinity-Based Methods for Site-Specific Conjugation of Antibodies," Bioconjugate chemistry, vol. 32, s. 1515-1524, 2021.

[30]

S. M. Mangsbo et al., "An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses," PLOS ONE, vol. 16, no. 9, 2021.

[31]

J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.

[32]

S. Havervall et al., "Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2," EBioMedicine, vol. 70, 2021.

[33]

K. A. Högelin et al., "Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis," iScience, vol. 24, no. 9, 2021.

[34]

K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.

[35]

N. Kharlamova et al., "False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases," Frontiers in Immunology, vol. 12, 2021.

[36]

J. Dillner et al., "High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers," The Journal of Infectious Diseases, vol. 224, no. 1, s. 14-20, 2021.

[37]

J. Scheffel och S. Hober, "Highly selective Protein A resin allows for mild sodium chloride-mediated elution of antibodies," Journal of Chromatography A, vol. 1637, 2021.

[38]

H. Alkharaan et al., "Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19 : A Complementary Approach to Population Surveys," Journal of Infectious Diseases, vol. 224, no. 3, s. 407-414, 2021.

[39]

O. Bragina et al., "Phase I Study of Tc-99(m)-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer," Journal of Nuclear Medicine, vol. 62, no. 4, s. 493-499, 2021.

[40]

J. Garousi et al., "Radionuclide therapy using ABD-fused ADAPT scaffold protein : Proof of Principle," Biomaterials, vol. 266, 2021.

[41]

S. Klevebro et al., "Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care," Scandinavian Journal of Public Health, vol. 49, no. 7, s. 707-712, 2021.

[42]

S. Hassan et al., "SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden," Journal of Internal Medicine, vol. 290, no. 2, s. 430-436, 2021.

[43]

P. Bergman et al., "Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial," EBioMedicine, vol. 74, s. 103705, 2021.

[44]

M. Ding et al., "Secretome screening reveals immunomodulating functions of IFNα-7, PAP and GDF-7 on regulatory T-cells," Scientific Reports, s. 16767, 2021.

[45]

E. von Witting et al., "Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension," Molecular Pharmaceutics, vol. 18, no. 1, s. 328-337, 2021.

[46]

S. Havervall et al., "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers," Journal of the American Medical Association (JAMA), vol. 325, s. 2015, 2021.

[47]

S. Hober et al., "Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay," Clinical & Translational Immunology (CTI), vol. 10, no. 7, 2021.

[48]

J. Garousi et al., "Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein," Pharmaceutics, vol. 13, no. 11, s. 1847, 2021.

[49]

H. Ding et al., "HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions : Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution," Pharmaceutics, vol. 12, no. 4, 2020.

[50]

H. Tegel et al., "High throughput generation of a resource of the human secretome in mammalian cells," New Biotechnology, vol. 58, s. 45-54, 2020.

[51]

S. Kanje et al., "Improvements of a high-throughput protein purification process using a calcium-dependent setup," Protein Expression and Purification, vol. 175, 2020.

[52]

A. Vorobyeva et al., "Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein," Molecules, vol. 25, no. 19, 2020.

[53]

A.-S. Rudberg et al., "SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.," Nature Communications, vol. 11, no. 1, 2020.

[54]

M. Ding et al., "Secretome-Based Screening in Target Discovery," SLAS Discovery, vol. 25, no. 6, s. 535-551, 2020.

[55]

S. Hober, S. Lindbo och J. Nilvebrant, "Bispecific applications of non-immunoglobulin scaffold binders," Methods, vol. 154, s. 143-152, 2019.

[56]

J. Garousi et al., "Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours," European journal of pharmaceutics and biopharmaceutics, vol. 134, s. 37-48, 2019.

[57]

J. Scheffel et al., "Optimization of a calcium-dependent Protein A-derived domain for mild antibody purification," mAbs, 2019.

[58]

K. Jennbacken et al., "Phenotypic Screen with the Human Secretome Identifies FGF16 as Inducing Proliferation of iPSC-Derived Cardiac Progenitor Cells," International Journal of Molecular Sciences, vol. 20, no. 23, 2019.

[59]

H. Liu et al., "Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A," International Journal of Oncology, vol. 55, no. 1, s. 309-319, 2019.

[60]

E. von Witting et al., "Selection of the optimal macrocyclic chelators for labeling with In-111 and Ga-68 improves contrast of HER2 imaging using engineered scaffold protein ADAPT6," European journal of pharmaceutics and biopharmaceutics, vol. 140, s. 109-120, 2019.

[61]

M. Uhlén et al., "The human secretome," Science Signaling, vol. 12, no. 609, 2019.

[62]

F. Edfors et al., "Enhanced validation of antibodies for research applications," Nature Communications, vol. 9, 2018.

[63]

S. Lindbo et al., "Optimized molecular design of ADAPT-based HER2-imaging probes labelled with ¹¹¹In and ⁶⁸Ga," Molecular Pharmaceutics, vol. 15, no. 7, s. 2674-2683, 2018.

[64]

S. Kanje et al., "Protein engineering allows for mild affinity-based elution of therapeutic antibodies," Journal of Molecular Biology, vol. 430, no. 18, s. 3427-3438, 2018.

[65]

Y.-T. Wu et al., "Quantum Dot-Based FRET Immunoassay for HER2 Using Ultrasmall Affinity Proteins," Small, vol. 14, no. 35, 2018.

[66]

S. Lindbo et al., "Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins : Aspects of Label Positioning and Residualizing Properties of the Label," Journal of Nuclear Medicine, vol. 59, no. 1, s. 93-99, 2018.

[67]

M. Uhlén et al., "A pathology atlas of the human cancer transcriptome," Science, vol. 357, no. 6352, s. 660-+, 2017.

[68]

P. J. Thul et al., "A subcellular map of the human proteome," Science, vol. 356, no. 6340, 2017.

[69]

J. Garousi et al., "Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m," Scientific Reports, vol. 7, 2017.

[70]

T. Boström, J. Ottosson Takanen och S. Hober, "Antibodies as means for selective mass spectrometry," Journal of chromatography. B, vol. 1021, s. 3-13, 2016.

[71]

S. Lindbo et al., "Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins.," Bioconjugate chemistry, vol. 27, no. 3, s. 716-726, 2016.

[72]

J. Garousi et al., "Influence of the N -Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6," Bioconjugate chemistry, vol. 27, no. 11, s. 2678-2688, 2016.

[73]

J. Garousi et al., "Influence of the N-terminal amino acid sequence on imaging properties of In-111-labeled anti-HER2 scaffold protein ADAPT6," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, s. S55-S55, 2016.

[74]

M. Åstrand et al., "Investigating affinity-maturation strategies and reproducibility of fluorescence-activated cell sorting using a recombinant ADAPT library displayed on staphylococci," Protein Engineering Design & Selection, vol. 29, no. 5, s. 187-195, 2016.

[75]

S. Kanje et al., "Next generation of labeling reagents for quantitative and multiplexing immunoassays by the use of LA-ICP-MS," ANALYST, vol. 141, no. 23, s. 6374-6380, 2016.

[76]

S. Kanje et al., "Site-Specific Photolabeling of the IgG Fab Fragment Using a Small Protein G Derived Domain," Bioconjugate chemistry, 2016.

[77]

J. Garousi et al., "ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers," Cancer Research, vol. 75, no. 20, s. 4364-4371, 2015.

[78]

X. Wang et al., "Association of chromosome 19 to lung cancer genotypes and phenotypes," Cancer Metastasis Review, vol. 34, no. 2, s. 217-226, 2015.

[79]

X. Wang et al., "Association of chromosome 19 to lung cancer genotypes and phenotypes (vol 34, pg 217, 2015)," Cancer Metastasis Review, vol. 34, no. 2, s. 227-227, 2015.

[80]

S. Kanje och S. Hober, "In vivo biotinylation and incorporation of a photo-inducible unnatural amino acid to an antibody-binding domain improve site-specific labeling of antibodies," Biotechnology Journal, vol. 10, no. 4, s. 564-574, 2015.

[81]

M. Uhlén et al., "Tissue-based map of the human proteome," Science, vol. 347, no. 6220, s. 1260419, 2015.

[82]

C. L. Nilsson et al., "Use of ENCODE Resources to Characterize Novel Proteoforms and Missing Proteins in the Human Proteome," Journal of Proteome Research, vol. 14, no. 2, s. 603-608, 2015.

[83]

J. Nilvebrant, M. Åstrand och S. Hober, "An orthogonal fusion tag for efficient protein purification," Methods in Molecular Biology, vol. 1129, s. 205-210, 2014.

[84]

C. Älgenäs et al., "Antibody performance in western blot applications is context- dependent," Biotechnology Journal, vol. 9, no. 3, s. 435-445, 2014.

[85]

J. Garousi et al., "Development of ADAPT6 as a new scaffold protein for radionuclide molecular imaging," European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, s. S309-S309, 2014.

[86]

J. Nilvebrant et al., "Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to Albumin," PLOS ONE, vol. 9, no. 8, s. e103094, 2014.

[87]

F. Edfors et al., "Immunoproteomics using polyclonal antibodies and stable isotope-labeled affinity-purified recombinant proteins," Molecular & Cellular Proteomics, vol. 13, no. 6, s. 1611-1624, 2014.

[88]

C. F. Lichti et al., "Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines," Journal of Proteome Research, vol. 13, no. 1, s. 191-199, 2014.

[89]

T. Boström et al., "Investigating the Applicability of Antibodies Generated within the Human Protein Atlas as Capture Agents in Immunoenrichment Coupled to Mass Spectrometry," Journal of Proteome Research, vol. 13, no. 10, s. 4424-4435, 2014.

[90]

M. Hedhammar, J. Nilvebrant och S. Hober, "Zbasic: a purification tag for selective ion-exchange recovery," Methods in Molecular Biology, vol. 1129, s. 197-204, 2014.

[91]

S. Andersson et al., "Antibodies Biotinylated Using a Synthetic Z-domain from Protein A Provide Stringent In Situ Protein Detection," Journal of Histochemistry and Cytochemistry, vol. 61, no. 11, s. 773-784, 2013.

[92]

C. L. Nilsson et al., "Chromosome 19 Annotations with Disease Speciation : A First Report from the Global Research Consortium," Journal of Proteome Research, vol. 12, no. 1, s. 134-149, 2013.

[93]

L. Fagerberg et al., "Contribution of antibody-based protein profiling to the human chromosome-centric proteome project (C-HPP)," Journal of Proteome Research, vol. 12, no. 6, s. 2439-2448, 2013.

[94]

J. Nilvebrant et al., "Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3," Cellular and Molecular Life Sciences (CMLS), vol. 70, no. 20, s. 3973-3985, 2013.

[95]

J. Malm et al., "Developments in biobanking workflow standardization providing sample integrity and stability," Journal of Proteomics, vol. 95, no. SI, s. 38-45, 2013.

[96]

J. Nilvebrant och S. Hober, "The albumin-binding domain as a scaffold for protein engineering," Computational and Structural Biotechnology Journal, vol. 6, no. 7, s. a5, 2013.

[97]

B. Adler et al., "Miniaturized and Automated High-Throughput Verification of Proteins in the ISET Platform with MALDI MS," Analytical Chemistry, vol. 84, no. 20, s. 8663-8669, 2012.

[98]

J. Nilvebrant, T. Alm och S. Hober, "Orthogonal protein purification facilitated by a small bispecific affinity tag," Journal of Visualized Experiments, no. 59, s. 1-5, 2012.

[99]

K. Colwill et al., "A roadmap to generate renewable protein binders to the human proteome," Nature Methods, vol. 8, no. 7, s. 551-8, 2011.

[100]

A. Konrad, A. Eriksson Karlström och S. Hober, "Covalent Immunoglobulin Labeling through a Photoactivable Synthetic Z Domain," Bioconjugate chemistry, vol. 22, no. 12, s. 2395-2403, 2011.

[101]

J. Nilvebrant et al., "Engineering Bispecificity into a Single Albumin-Binding Domain," PLOS ONE, vol. 6, no. 10, s. e25791, 2011.

[102]

H. Tegel, J. Ottosson och S. Hober, "Enhancing the protein production levels in Escherichia coli with a strong promoter," The FEBS Journal, vol. 278, no. 5, s. 729-739, 2011.

[103]

B. Hjelm et al., "High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer," Proteomics. Clinical applications, vol. 5, no. 11-12, s. 624-35, 2011.

[104]

K. Larsson et al., "Novel antigen design for the generation of antibodies to G-protein-coupled receptors," JIM - Journal of Immunological Methods, vol. 370, no. 1-2, s. 14-23, 2011.

[105]

H. Tegel et al., "Parallel production and verification of protein products using a novel high-throughput screening method," Biotechnology Journal, vol. 6, no. 8, s. 1018-1025, 2011.

[106]

E. Gustavsson et al., "Surrogate antigens as targets for proteome-wide binder selection," New Biotechnology, vol. 28, no. 4, s. 302-311, 2011.

[107]

R. Falk et al., "Targeted protein pullout from human tissue samples using competitive elution," Biotechnology Journal, vol. 6, no. 1, s. 28-37, 2011.

[108]

P. L. Ståhl et al., "Translational Database Selection and Multiplexed Sequence Capture for Up Front Filtering of Reliable Breast Cancer Biomarker Candidates," PLOS ONE, vol. 6, no. 6, s. e20794, 2011.

[109]

T. Alm et al., "A small bispecific protein selected for orthogonal affinity purification," BIOTECHNOL J, vol. 5, no. 6, s. 605-617, 2010.

[110]

C. Eriksson et al., "Affibody molecule-mediated depletion of HSA and IgG using different buffer compositions : a 15 min protocol for parallel processing of 1-48 samples," Biotechnology and applied biochemistry, vol. 56, s. 49-57, 2010.

[111]

L. Paavilainen et al., "The Impact of Tissue Fixatives on Morphology and Antibody-based Protein Profiling in Tissues and Cells," Journal of Histochemistry and Cytochemistry, vol. 58, no. 3, s. 237-246, 2010.

[112]

M. Uhlén et al., "Towards a knowledge-based Human Protein Atlas," Nature Biotechnology, vol. 28, no. 12, s. 1248-1250, 2010.

[113]

F. Ponten et al., "A global view of protein expression in human cells, tissues, and organs," Molecular Systems Biology, vol. 5, 2009.

[114]

J. Steen et al., "Automated sample preparation method for mass spectrometry analysis on recombinant proteins," Journal of Chromatography A, vol. 1216, no. 20, s. 4457-4464, 2009.

[115]

K. Larsson et al., "Characterization of PrEST-based antibodies towards human Cytokeratin-17," JIM - Journal of Immunological Methods, vol. 342, s. 20-32, 2009.

[116]

M. Ramström et al., "Development of affinity columns for the removal of high-abundance proteins in cerebrospinal fluid," Biotechnology and applied biochemistry, vol. 52, no. 2, s. 159-166, 2009.

[117]

M. Uhlén och S. Hober, "Generation and validation of affinity reagents on a proteome-wide level," Journal of Molecular Recognition, vol. 22, no. 2, s. 57-64, 2009.

[118]

H. Tegel et al., "High-throughput protein production--lessons from scaling up from 10 to 288 recombinant proteins per week," Biotechnology Journal, vol. 4, no. 1, s. 51-57, 2009.

[119]

J. Mulder et al., "Tissue Profiling of the Mammalian Central Nervous System Using Human Antibody-based Proteomics," Molecular & Cellular Proteomics, vol. 8, no. 7, s. 1612-1622, 2009.

[120]

L. Berglund et al., "A genecentric human protein atlas for expression profiles based on antibodies," Molecular & Cellular Proteomics, vol. 7, no. 10, s. 2019-2027, 2008.

[121]

E. Björling et al., "A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues," Molecular & Cellular Proteomics, vol. 7, no. 5, s. 825-844, 2008.

[122]

L. Paavilainen et al., "Evaluation of monospecific antibodies : A comparison study with commercial analogs using immunohistochemistry on tissue microarrays," Applied immunohistochemistry & molecular morphology (Print), vol. 16, no. 5, s. 493-502, 2008.

[123]

S. Hober och M. Uhlén, "Human protein atlas and the use of microarray technologies," Current Opinion in Biotechnology, vol. 19, no. 1, s. 30-35, 2008.

[124]

A. S. Rajangam et al., "MAP20, a Microtubule-Associated Protein in the Secondary Cell Walls of Hybrid Aspen, Is a Target of the Cellulose Synthesis Inhibitor 2,6-Dichlorobenzonitrile," Plant Physiology, vol. 148, no. 3, s. 1283-1294, 2008.

[125]

C. Grönwall et al., "Affibody-mediated transferrin depletion for proteomics applications," Biotechnology Journal, vol. 2, no. 11, s. 1389-1398, 2007.

[126]

R. Falk et al., "Approaches for systematic proteome exploration," Biomolecular Engineering, vol. 24, no. 2, s. 155-168, 2007.

[127]

T. Alm et al., "High-throughput protein purification under denaturating conditions by the use of cation exchange chromatography," Biotechnology Journal, vol. 2, s. 709-716, 2007.

[128]

S. Hober, K. Nord och M. Linhult, "Protein A chromatography for antibody purification," Journal of chromatography. B, vol. 848, no. 1, s. 40-47, 2007.

[129]

J. Mulder et al., "Systematically generated antibodies against human gene products : High throughput screening on sections from the rat nervous system," Neuroscience, vol. 146, no. 4, s. 1689-1703, 2007.

[130]

M. Lerner et al., "The RBCC gene RFP2 (leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD," Molecular Biology of the Cell, vol. 18, no. 5, s. 1670-1682, 2007.

[131]

M. Hedhammar och S. Hober, "Z(basic) - A novel purification tag for efficient protein recovery," Journal of Chromatography A, vol. 1161, no. 1-2, s. 22-28, 2007.

[132]

A. Persson, S. Hober och M. Uhlén, "A human protein atlas based on antibody proteomics," Current opinion in molecular therapeutics (Print), vol. 8, no. 3, s. 185-190, 2006.

[133]

M. Hedhammar, H. R. Jung och S. Hober, "Enzymatic cleavage of fusion proteins using immobilised protease 3C," Protein Expression and Purification, vol. 47, no. 2, s. 422-426, 2006.

[134]

S. Ek et al., "From gene expression analysis to tissue microarrays - A rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies," Molecular & Cellular Proteomics, vol. 5, no. 6, s. 1072-1081, 2006.

[135]

J. Steen et al., "High-throughput protein purification using an automated set-up for high-yield affinity chromatography," Protein Expression and Purification, vol. 46, no. 2, s. 173-178, 2006.

[136]

C. Eriksson et al., "Microfluidic analysis of antibody specificity in a compact disk format," Journal of Proteome Research, vol. 5, no. 7, s. 1568-1574, 2006.

[137]

K. Larsson et al., "Multiplexed PrEST immunization for high-throughput affinity proteomics," JIM - Journal of Immunological Methods, vol. 315, s. 110-120, 2006.

[138]

A. Ahmadian, M. Ehn och S. Hober, "Pyrosequencing : History, biochemistry and future," Clinica Chimica Acta, vol. 363, no. 02-jan, s. 83-94, 2006.

[139]

M. Hedhammar et al., "Single-step recovery and solid-phase refolding of inclusion body proteins using a polycationic purification tag," Biotechnology Journal, vol. 1, s. 187-196, 2006.

[140]

M. Hedhammar et al., "A Novel flow cytometry-based method for analysis of expression levels in Escherichia coli, giving information about precipitated and soluble protein," Journal of Biotechnology, vol. 119, no. 2, s. 133-146, 2005.

[141]

M. Uhlén et al., "A human protein atlas for normal and cancer tissues based on antibody proteomics," Molecular & Cellular Proteomics, vol. 4, no. 12, s. 1920-1932, 2005.

[142]

M. Linhult, S. Gulich och S. Hober, "Affinity ligands for industrial protein purification," Protein peptide letters, vol. 12, no. 4, s. 305-310, 2005.

[143]

M. Boström et al., "Effect of substrate feed rate on recombinant protein secretion, degradation and invlusion body formation in Escherichia coli," Applied Microbiology and Biotechnology, vol. 68, no. 1, s. 82-90, 2005.

[144]

M. Stenvall et al., "High-throughput solubility assay for purified recombinant protein immunogens," Biochimica et Biophysica Acta - Proteins and Proteomics, vol. 1752, no. 1, s. 6-10, 2005.

[145]

M. Hedhammar, T. Gräslund och S. Hober, "Protein engineering strategies for selective protein purification," Chemical Engineering & Technology, vol. 28, no. 11, s. 1315-1325, 2005.

[146]

P. Nilsson et al., "Towards a human proteome atlas : High-throughput generation of mono-specific antibodies for tissue profiling," Proteomics, vol. 5, s. 4327-4337, 2005.

[147]

C. Agaton, M. Uhlén och S. Hober, "Genome-based proteomics," Electrophoresis, vol. 25, no. 9, s. 1280-1288, 2004.

[148]

M. Linhult et al., "Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach," Proteins : Structure, Function, and Bioinformatics, vol. 55, no. 2, s. 407-416, 2004.

[149]

M. Hedhammar et al., "Negatively charged purification tags for selective anion-exchange recovery," Protein Engineering Design & Selection, vol. 17, no. 11, s. 779-786, 2004.

[150]

C. Agaton et al., "Selective enrichment of monospecific polyclonal antibodies for antibody-based proteomics efforts," Journal of Chromatography A, vol. 1043, s. 33-40, 2004.

[151]

M. Ehn et al., "Toward pyrosequencing on surface-attached genetic material by use of DNA-binding luciferase fusion proteins," Analytical Biochemistry, vol. 329, no. 1, s. 11-20, 2004.

[152]

R. Falk et al., "An improved dual-expression concept, generating high-quality antibodies for proteomics research," Biotechnology and applied biochemistry, vol. 38, s. 231-239, 2003.

[153]

M. Linhult et al., "Evaluation of different linker regions for multimerization and coupling chemistry for immobilization of a proteinaceous affinity ligand," Protein Engineering, vol. 16, no. 12, s. 1147-1152, 2003.

[154]

N. Nourizad et al., "Methylotrophic yeast Pichia pastoris as a host for production of ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum)," Protein Expression and Purification, vol. 27, no. 2, s. 229-237, 2003.

[155]

S. Gulich et al., "Engineering streptococcal protein G for increased alkaline stability," Protein Engineering, vol. 15, no. 10, s. 835-842, 2002.

[156]

M. Ehn et al., "Escherichia coli single-stranded DNA-binding a molecular tool for improved sequence protein quality in pyrosequencing," Electrophoresis, vol. 23, no. 19, s. 3289-3299, 2002.

[157]

T. Gräslund et al., "Integrated strategy for selective expanded bed ion-exchange adsorption and site-specific protein processing using gene fusion technology," Journal of Biotechnology, vol. 96, no. 1, s. 93-102, 2002.

[158]

[159]

M. Linhult et al., "Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin," Protein Science, vol. 11, no. 2, s. 206-213, 2002.

[160]

T. Gräslund et al., "Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner," Journal of Chromatography A, vol. 942, no. 1-2, s. 157-166, 2002.

[161]

M. U. Johansson et al., "Structure, specificity, and mode of interaction for bacterial albumin-binding modules," Journal of Biological Chemistry, vol. 277, no. 10, s. 8114-8120, 2002.

[162]

M. Ehn et al., "Overexpression, rapid isolation, and biochemical characterization of Escherichia coli single-stranded DNA-binding protein," Protein Expression and Purification, vol. 22, no. 1, s. 120-127, 2001.

[163]

T. Gräslund et al., "Charge engineering of a protein domain to allow efficient ion-exchange recovery," Protein Engineering, vol. 13, no. 10, s. 703-709, 2000.

[164]

S. Gulich, M. Uhlén och S. Hober, "Protein engineering of an IgG-binding domain allows milder elution conditions during affinity chromatography," Journal of Biotechnology, vol. 76, no. 03-feb, s. 233-244, 2000.

[165]

S. Gulich et al., "Stability towards alkaline conditions can be engineered into a protein ligand," Journal of Biotechnology, vol. 80, no. 2, s. 169-178, 2000.

[166]

S. Hober et al., "Insulin-like growth factors I and II are unable to form and maintain their native disulfides under in vivo redox conditions.," FEBS Letters, vol. 443, no. 3, 1999.

[167]

K. Andersson et al., "Kinetic characterization of the interaction of the Z-fragment of protein A with mouse-IgG3 in a volume in chemical space.," Proteins : Structure, Function, and Bioinformatics, vol. 37, no. 3, 1999.

[168]

S. Hober et al., "Folding of insulin-like growth factor I is thermodynamically controlled by insulin-like growth factor binding protein.," Biochemistry, vol. 33, no. 22, 1994.

[169]

S. Hober et al., "Disulfide exchange folding of insulin-like growth factor I.," Biochemistry, vol. 31, no. 6, 1992.

[170]

L. Strandberg et al., "Expression and characterization of a tripartite fusion protein consisting of chimeric IgG-binding receptors and beta-galactosidase," Journal of Biotechnology, vol. 13, no. 1, s. 83-96, 1990.

Kapitel i böcker

[171]

J. Nilvebrant, M. Åstrand och S. Hober, "An orthogonal fusion tag for efficient protein purification," i Methods in Molecular Biology, NaN. uppl. : Springer Nature, 2021, s. 159-166.

[172]

J. Scheffel, S. Kanje och S. Hober, "ZCa : A protein A-derived domain with calcium-dependent affinity for mild antibody purification," i Methods in Molecular Biology, NaN. uppl. : Humana Press Inc., 2021, s. 245-249.

[173]

M. Hedhammar, J. Nilvebrant och S. Hober, "Zbasic : A Purification Tag for Selective Ion-Exchange Recovery," i Protein Downstream Processing : Design, Development, and Application of High and Low-Resolution Methods, : Humana Press, 2021, s. 149-158.

[174]

T. Boström, J. Nilvebrant och S. Hober, "Purification systems based of bacterial surface proteins," i Protein Purification, Rizwan Ahmad red., : InTech, 2012, s. 89-136.

Icke refereegranskade

Artiklar

[175]

K. A. Hogelin et al., "Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, s. 348-348, 2021.

[176]

O. Bragina et al., "Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S9-S9, 2020.

[177]

J. Garousi et al., "Radionuclide Therapy Using Lu-177-labeled ABD-fused ADAPT6 Scaffold Protein," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S649-S650, 2020.

[178]

V. Tolmachev et al., "First-in-humans Evaluation of [Tc-99m]-ADAPT6, a Novel Scaffold Protein for Visualizationof HER2 Expression," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, s. S166-S166, 2019.

[179]

J. Garousi et al., "Selection Of The Optimal Macrocyclic Chelators For Labelling With In-111 And Ga-68 Improves Contrast Of Her2 Imaging Using Engineered Scaffold Protein Adapt6," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, s. S131-S131, 2019.

[180]

V. Tolmachev et al., "Selection of the optimal macrocyclic chelators for labelling with In-111 and Ga-68 improves contrast of HER2 imaging using engineered scaffold protein ADAPT6," Journal of labelled compounds & radiopharmaceuticals, vol. 62, s. S100-S101, 2019.

[181]

J. Garousi et al., "Selection of the most optimal ADAPT6-based probe for imaging of HER2 using PET and SPECT," European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, s. S77-S78, 2018.

[182]

J. Garousi et al., "Radionuclide tumor targeting using ADAPT scaffold proteins : aspects of label positioning and residualizing properties of the label," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, s. S228-S229, 2017.

[183]

S. Hober, "Biotech reviews on plants, lignocellulose, sequencing, genome engineering and Aspergilli," Biotechnology Journal, vol. 7, no. 9, s. 1057-1057, 2012.

[184]

S. Hober, "Biotech reviews : keeping up with current developments," Biotechnology Journal, vol. 6, 2011.

[185]

S. Hober, "Global biotech challenges," Biotechnology Journal, vol. 5, 2010.

[186]

S. Hober, "Progress in production and purification of proteins," The FEBS Journal, vol. 277, s. 15-15, 2010.

[187]

S. Hober, "Biotech in the post genomic era," Biotechnology Journal, vol. 4, s. 1631, 2009.

[188]

H. Tegel et al., "Flow cytometry-based analysis of promoter effects on solubility of recombinantly expressed proteins," Journal of Biotechnology, vol. 131, no. 2, s. S9-S9, 2007.

[189]

J. Ottosson et al., "High throughput protein production and purification in the Human Protein Atlas program," Molecular & Cellular Proteomics, vol. 5, no. 10, s. S40-S40, 2006.

[190]

C. Eriksson et al., "Microfluidic analysis of antibodies in a compact disc format," Molecular & Cellular Proteomics, vol. 4, no. 8, s. S47-S47, 2005.

[191]

H. Tegel et al., "Novel flow cytometry-based method for analysis of protein production in Escherichia coli," Molecular & Cellular Proteomics, vol. 4, no. 8, s. S66-S66, 2005.

[192]

J. Ottosson et al., "High throughput protein expression and purification for antibody proteomics," Molecular & Cellular Proteomics, vol. 3, no. 10, s. S169-S169, 2004.

[193]

R. Falk et al., "Selective enrichment of monospecific polyclonal antibodies for antibody-based proteomics efforts - Abstracts," Molecular & Cellular Proteomics, vol. 3, no. 10, s. S1-S1, 2004.

Kapitel i böcker

[194]

S. Kanje et al., "Engineering of Protein A for improved purification of antibodies and Fc-fused proteins," i Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics, : Elsevier, 2020, s. 35-54.